✦ LIBER ✦

Comparison of CHOP-B vs CEOP-B in ‘poor prognosis’ non-Hodgkin’s lymphomas. A randomized trial

✍ Scribed by De Lena, Mario ;Maiello, Evaristo ;Lorusso, Vito ;Brandi, Mario ;Calabrese, Piero ;Romito, Sante ;Mazzei, Antonio ;Marzullo, Franco

Book ID: 112962912
Publisher: Springer-Verlag
Year: 1989
Weight: 501 KB
Volume: 6
Category: Article
ISSN: 0736-0118
DOI: 10.1007/bf02985240

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CHOP vs MEV for the treatment of non-Hod

CHOP vs MEV for the treatment of non-Hodgkin's lymphoma of unfavourable histopathology: A randomized clinical trial

✍ Hagberg, H.; Björkholm, M.; Glimelius, B.; Lindemalm, Ch.; Mellstedt, H.; Killan 📂 Article 📅 1985 🏛 Elsevier Science ⚖ 516 KB

CHOP vs. ProMACE-CytaBOM in the treatmen

CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial

✍ E. Montserrat; J. García-Conde; N. Viñolas; A. López-Guillermo; L. Hernández-Nie 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 533 KB

A pilot study of cyclical chemotherapy w

A pilot study of cyclical chemotherapy with high-dose methotrexate and CHOP (MTX-CHOP) in poor-prognosis non-Hodgkin's lymphoma (NHL)

✍ J. A. Child; D. L. Barnard; S. C. Cartwright; I. Lauder; A. V. Simmons; J. Stone 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 622 KB

A revisit of prophylactic lamivudine for

A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial

✍ Chiun Hsu; Chao A. Hsiung; Ih-Jen Su; Wei-Shou Hwang; Ming-Chung Wang; Sheng-Fun 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 716 KB

Lamivudine is effective to control hepatitis B virus (HBV) reactivation in HBV-carrying cancer patients who undergo chemotherapy, but the optimal treatment protocol remains undetermined. In this study, HBV carriers with newly diagnosed non-Hodgkin's lymphoma (NHL) who underwent chemotherapy were ran

A phase III comparison of CHOP vs. m-BAC

A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: Results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study

✍ Fisher, R. I.; Gaynor, E. R.; Dahlberg, S.; Oken, M. M.; Grogan, T. M.; Mize, E. 📂 Article 📅 1994 🏛 Oxford University Press 🌐 English ⚖ 522 KB

Structural aberrations affecting the MYC

Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

✍ Klapper, W; Stoecklein, H; Zeynalova, S; Ott, G; Kosari, F; Rosenwald, A; Loeffl 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 136 KB